Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASCO1: TAS-102 plus bevacizumab versus capecitabine plus bevacizumab in first-line metastatic colorectal cancer
NL-OMON43475Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing TAS-102 + bevacizumab with Capecitabine + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2016; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilbevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON43475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43475.